SCIVISION BIOTECH INC.

Communiqués SciVision Biotech Inc.

Actions

1786

TW0001786002

Cours en clôture Taiwan S.E. Autres places de cotation 00:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
123,5 ^TWD	+4,66 %		+2,49 %	+59,15 %

26/06	SciVision Biotech Inc. approuve un dividende en espèces, payable le 16 août 2024	CI
10/05	Le produit de Scivision Biotech Inc. "Hyajoint Plus", supplément de liquide synovial à base d'acide hyaluronique à injection unique, a obtenu une licence pour un dispositif médical	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SciVision Biotech : Announcement of the approval for recordation being granted by FSC on extended offering period of the second domestic unsecured convertible bonds	15/08/22	PU
SciVision Biotech : Announcement of the approval for recordation being granted by FSC on extended offering period of the second domestic unsecured convertible bonds For 3 Months	11/08/22	PU
SciVision Biotech : Announcement of board meeting approved the consolidated financial statements for the second quarter of 2022	03/08/22	PU
SciVision Biotech : Announcement of the company's financial officer, accounting officer and corporate governance officer approved by Board of Directors.	29/06/22	PU
SciVision Biotech : Announce the record date for cash dividend	29/06/22	PU
SciVision Biotech : Announcement the Important Resolutions in 2022 Annual General Meeting of Shareholders	29/06/22	PU
SciVision Biotech : The Company’s Product, hyaluronic acid Flexotron Forte (1%) has obtained medical device license.	09/06/22	PU
SciVision Biotech : The The Company’s Product, hyaluronic acid three-injection linear intra-articular implant, Flexotron Plus (2%) has obtained medical device license.	26/05/22	PU
SciVision Biotech : Board of Directors approved the convening of the 2022 Annual Shareholders' Meeting	23/03/22	PU
SciVision Biotech : The Company's Board of Directors resolved the dividend distributions	23/03/22	PU
SciVision Biotech : The Company's 2021 consolidated financial statements have been approved by the Board of Directors	23/03/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Sécurisez et Augmentez les Rendements de vos Investissements grâce à l'Accompagnement de Nos Experts

Sécuriser mes Investissements

fermer